Thiogenesis Therapeutics, Corp.

Thiogenesis Therapeutics (TSXV: TTI) is developing New Chemical Entities (NCEs) that are novel thiol compounds with strong antioxidant and anti-inflammatory properties; and that have the potential to be used as new therapeutic drugs for mitochondrial diseases including metabolic conditions like fatty liver disease, diabetes, etc. Oxidative stress and mitochondrial dysfunction are critical underlying features of mitochondrial diseases. Thiols are compounds that have an active (-SH) functional group that participates in several biochemical reactions. The foremost potential therapeutic benefit of TTI-0102, is as the best-in-class method of generating the most important intracellular antioxidant - glutathione. TTI-0102 is classified as a prodrug because its active moiety has been previously approved and is only biologically activated after oral administration. As a result, TTI-0102 can utilize the accelerated 505(b)(2) regulatory pathway in the United States and its equivalent in Europe, saving significant time and cost. Thiogenesis is initially targeting pediatric diseases with unmet medical needs, that have oxidative stress as a core component and for which there is no approved therapy. With regulatory approval, the Company anticipates the initiation of three human efficacy trials with leading research institutions: in the metabolic liver disease pediatric MASLD/MASH and the inherited mitochondrial diseases MELAS and Leigh syndrome.